Compare · ABCM vs TECH
ABCM vs TECH
Side-by-side comparison of Abcam plc (ABCM) and Bio-Techne Corp (TECH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABCM and TECH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- TECH is the larger of the two at $8.79B, about 1.9x ABCM ($4.59B).
- TECH has hit the wire 4 times in the past 4 weeks while ABCM has been quiet.
- TECH has more recent analyst coverage (24 ratings vs 3 for ABCM).
- Company
- Abcam plc
- Bio-Techne Corp
- Price
- $23.98+0.00%
- $56.15+3.96%
- Market cap
- $4.59B
- $8.79B
- 1M return
- -
- +25.47%
- 1Y return
- -
- +8.71%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 4
- Recent ratings
- 3
- 24
Abcam plc
Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Latest ABCM
- SEC Form SC 13G/A filed by Abcam plc (Amendment)
- SEC Form SC 13G/A filed by Abcam plc (Amendment)
- SEC Form 15-12G filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form S-8 POS filed by Abcam plc
- SEC Form POSASR filed by Abcam plc
- SEC Form SC 13D/A filed by Abcam plc (Amendment)
- SEC Form 25-NSE filed by Abcam plc
- Danaher Completes Acquisition of Abcam
Latest TECH
- Piper Sandler initiated coverage on Bio-Techne with a new price target
- President - Diag & Spatial Bi Crouse Steven C. converted options into 600 shares and covered exercise/tax liability with 216 shares, increasing direct ownership by 6% to 6,761 units (SEC Form 4)
- Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
- SEC Form SD filed by Bio-Techne Corp
- RBC Capital Mkts resumed coverage on Bio-Techne with a new price target
- Director Herr Amy E. sold $320,386 worth of shares (6,636 units at $48.28) and exercised 6,636 shares at a strike of $47.60 (SEC Form 4)
- CFO Hippel James covered exercise/tax liability with 56,955 shares and exercised 62,000 shares at a strike of $47.60, increasing direct ownership by 3% to 153,670 units (SEC Form 4)
- SVP - General Counsel Bohnen Shane exercised 8,400 shares at a strike of $47.60 and covered exercise/tax liability with 7,055 shares, increasing direct ownership by 23% to 7,249 units (SEC Form 4)
- Chief Executive Officer Kelderman Kim exercised 26,692 shares at a strike of $47.60 and covered exercise/tax liability with 23,951 shares, increasing direct ownership by 4% to 65,799 units (SEC Form 4)
- Bio-Techne Declares Dividend